Fig. 2 (abstract P136a).From: 16th European Headache Congress 2022 meeting abstractsZavegepant Nasal Spray Versus Placebo in the Acute Treatment of Migraine: Pain Relief at 15, 30, 60, and 120 Minutes PostdoseBack to article page